This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article content
AUSTIN, Texas, Sept. 14, 2026 (GLOBE NEWSWIRE) — via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” featuring Quantum BioPharma Ltd. (NASDAQ: QNTM).
Sign In or Create an Account
or View more offersArticle content
To hear the NetworkNewsAudio version, visit https://ibn.fm/NYGrX
Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content
To read the original editorial, visit: https://ibn.fm/w10cb
Article content
Even large, well-funded competitors are still searching for something better. Several major pharmaceutical companies have advanced new [multiple sclerosis] MS candidates through late-stage trials in recent years only to see mixed or disappointing results, including recent failures in the broader field of myelin repair. That track record underscores how difficult it remains to develop a therapy that changes the disease’s underlying course rather than just its symptoms. For patients, that means the wait for something that restores lost function, rather than merely slowing its loss, continues.
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
The FDA’s clearance of Quantum BioPharma’s Investigational New Drug (“IND”) application marks a genuinely rare moment in MS research. According to the company, the IND submission ran approximately 15,000 pages and includes a comprehensive package of pharmacology, toxicology and manufacturing data. With that clearance now secured, Quantum BioPharma can move directly into a randomized, double-blind, placebo-controlled phase 2 trial testing Lucid-MS in people suffering with MS.
Article contentArticle content
About Quantum BioPharma Ltd.
Article content
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
For further information, please visit the company’s website at www.QuantumBioPharma.com.
Article content
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Article content
About NetworkNewsAudio
Article content
NetworkNewsAudio, a service of NetworkNewsWire (NNW), a multifaceted financial news and publishing company powered by IBN (“InvestorBrandNetwork”), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.
Article content
For more information, visit: www.NetworkNewsAudio.com
Article content
NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today’s markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.